Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Novan Inc.

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102

After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.

Clinical Trials Research & Development

Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb

Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.

Commercial Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Novan Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novan Inc.
  • Senior Management
  • G. Kelly Martin, CEO
    William Hodges, Interim CFO
    Nathan Stasko, PhD, Pres. & CSO
    Jeff N Hunter, EVP, CBO
    Kevin Barber, VP, Reg Affairs
    Brian Johnson, Chief Commercial Officer
    Paula Brown Stafford, Chief Dev. Officer
    Stanley Hollenbach, SVP, R&D
    Carri Geer, VP, Pharma Dev
    Tim O'Sullivan, VP, Intellectual Capital
  • Contact Info
  • Novan Inc.
    Phone: (919) 485-8080
    4105 Hopson Rd.
    Morrisville, NC 27560
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register